MicroRNA signatures discriminate between uterine and ovarian serous carcinomas

Hui, Pei; Gysler, Stefan; Uduman, Mohamed; Togun, Taiwo A.; Prado, Daniel Estévez; Brambs, Christine; Nallur, Sunitha; Schwartz, Peter E.; Rutherford, Thomas J.; Santin, Alessandro D.; Weidhaas, Joanne B.; Ratner, Elena

doi:10.1016/j.humpath.2018.02.019

Cited by 11 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results demonstrate the overlap in IHC expression between serous carcinomas arising at the 2 primary sites such that it is insufficiently discriminatory to allow accurate diagnosis of primary site in an individual case. Differences in gene expression profiling and microRNA signatures have been put forward as potential discriminatory tools to separate tubo-ovarian HGSC from ESC but are not clinically applicable at this time 47,48 …”

Section: Case Presentationmentioning

confidence: 99%

“…Differences in gene expression profiling and microRNA signatures have been put forward as potential discriminatory tools to separate tubo-ovarian HGSC from ESC but are not clinically applicable at this time. 47,48 In summary there are currently no robust clinical, morphological, or biomarker features that separate HGSC of endometrial from that of tubo-ovarian origin in instances where both the endometrium and fallopian tube epithelium are involved by disease. Specifically, intraepithelial carcinoma at either location can represent the primary lesion or secondary involvement, the presence of a dominant mass favors but is not sufficiently specific to determine one primary site over the other, and no biomarker has been proven to have sufficient specificity to enable accurate distinction between possible primary sites.…”

Section: High-grade Serous Carcinoma With Concurrent Involvement Of T...mentioning

confidence: 99%

See 1 more Smart Citation

Carcinomas With Concurrent Involvement of the Endometrium and Uterine Adnexa—Implications for Pathological Diagnosis and Clinical Management in Current Practice

Singh

Tinker

Gilks

2022

AJSP: Reviews and Reports

View full text Add to dashboard Cite

A proportion of endometrial and adnexal carcinomas have concurrent involvement of the other site. In the case of high-grade serous carcinomas involving the tubal epithelium as well as endometrium, distinction of tubo-ovarian high-grade serous from endometrial serous carcinoma can have implications for surgical as well as nonsurgical treatment approaches, including targeted therapies and referral to clinical genetics services. The other situation is involvement of the endometrium and ovary by low-grade endometrioid carcinoma; here separation of high-stage endometrial carcinoma from 2 low-stage, low-grade tumors determines adjuvant treatment decisions. These challenging scenarios are illustrated with case presentations and criteria for pathological reporting while acknowledging uncertainty where this is warranted. It is accepted that these are areas in transition, and any criteria offered are likely to change in the light of new information.

show abstract

Section: Case Presentationmentioning

confidence: 99%

Section: High-grade Serous Carcinoma With Concurrent Involvement Of T...mentioning

confidence: 99%

Carcinomas With Concurrent Involvement of the Endometrium and Uterine Adnexa—Implications for Pathological Diagnosis and Clinical Management in Current Practice

Singh

Tinker

Gilks

2022

AJSP: Reviews and Reports

View full text Add to dashboard Cite

show abstract

“…Despite the strong evidence on the oncogenic function of miR-196 in cancers, few reports have indicated that the miR-196 family can act as tumor suppressors in some cancers, such as melanoma and breast cancer (26). Some studies have suggested miR-196a as a noninvasive biomarker for diagnosis, staging and prognosis of cancers (27)(28)(29).…”

Section: Correlation Analysis Of the Mir-196a With Clinicopathologicamentioning

confidence: 99%

Expression Analysis of MicroRNA-196a in Esophageal Cancer

Maghsudlu

Yazd

Amiriani

2019

jcbr

View full text Add to dashboard Cite

Backgrounds and objectives: Esophageal squamous cell carcinoma (ESCC) is a prevalent subtype of esophageal cancer in certain areas of the world. Molecular evaluations can provide a better understanding of the disease that could contribute to earlier diagnosis and treatment. Amplification or absence of microRNA (miRNA) genes has been described in many types of cancer, indicating that altered patterns of miRNA expression may affect cell cycle and its features. In this study, we investigated alteration of miR-196a expression in ESCC tissues and its association with tumor status. Methods: The study was done on 30 specimens including matched tumor and normal tumor margin tissues. RNA extraction and complementary DNA synthesis were performed using specific primers. Quantitative PCR was done to assess the relative expression of miR-196a in tumor tissues of patients with ESCC. Data were normalized by expression level of SNORD gene as an internal control. The GraphPad Prism and SPSS software were used for analysis of data. Results: MiR-196a expression was higher in cancer tissues compared to normal tissues (P>0.05). The miRNA upregulation had no significant correlation with clinicopathological features such as age, gender and survival rate. Conclusion: The results of the present study indicate a nonsignificant increased expression of miR-196a in ESCC tumor specimen. Future studies with a larger sample size could confirm our findings.

show abstract

“…MiR-92a, miR-106a and miR-200b were upregulated in endometrial cancer cells compared to ovarian, and conversely miR-222 was upregulated in ovarian cancer cells compared to endometrial cancer cells [ 75 ]. Hui et al illustrated that miRNA signatures successfully differentiated uterine serous carcinomas from ovarian serous carcinomas [ 76 ]. Notwithstanding, if serous carcinoma is diagnosed at an advanced stage, distinction between primary and metastatic tumours often proves challenging [ 76 ].…”

Section: Introductionmentioning

confidence: 99%

“…Hui et al illustrated that miRNA signatures successfully differentiated uterine serous carcinomas from ovarian serous carcinomas [ 76 ]. Notwithstanding, if serous carcinoma is diagnosed at an advanced stage, distinction between primary and metastatic tumours often proves challenging [ 76 ]. Such factors have clinically significant implications as they effect decision-making in terms of treatment regimens for the patient.…”

Section: Introductionmentioning

confidence: 99%

The Potential of MicroRNAs as Clinical Biomarkers to Aid Ovarian Cancer Diagnosis and Treatment

Davies¹,

Davey²,

Miller³

2022

Genes

View full text Add to dashboard Cite

Ovarian cancer is a commonly diagnosed malignancy in women. When diagnosed at an early stage, survival outcomes are favourable for the vast majority, with up to 90% of ovarian cancer patients being free of disease at 5 years follow-up. Unfortunately, ovarian cancer is typically diagnosed at an advanced stage due to the majority of patients remaining asymptomatic until the cancer has metastasised, resulting in poor outcomes for the majority. While the molecular era has facilitated the subclassification of the disease into distinct clinical subtypes, ovarian cancer remains managed and treated as a single disease entity. MicroRNAs (miRNAs) are small (19–25 nucleotides), endogenous molecules which are integral to regulating gene expression. Aberrant miRNA expression profiles have been described in several cancers, and have been implicated to be useful biomarkers which may aid cancer diagnostics and treatment. Several preliminary studies have identified candidate tumour suppressor and oncogenic miRNAs which may be involved in the development and progression of ovarian cancer, highlighting their candidacy as oncological biomarkers; understanding the mechanisms by which these miRNAs regulate the key processes involved in oncogenesis can improve our overall understanding of cancer development and identify novel biomarkers and therapeutic targets. This review highlights the potential role of miRNAs which may be utilised to aid diagnosis, estimate prognosis and enhance therapeutic strategies in the management of primary ovarian cancer.

show abstract

MicroRNA signatures discriminate between uterine and ovarian serous carcinomas

Cited by 11 publications

References 39 publications

Carcinomas With Concurrent Involvement of the Endometrium and Uterine Adnexa—Implications for Pathological Diagnosis and Clinical Management in Current Practice

Carcinomas With Concurrent Involvement of the Endometrium and Uterine Adnexa—Implications for Pathological Diagnosis and Clinical Management in Current Practice

Expression Analysis of MicroRNA-196a in Esophageal Cancer

The Potential of MicroRNAs as Clinical Biomarkers to Aid Ovarian Cancer Diagnosis and Treatment

Contact Info

Product

Resources

About